OncoMatch

OncoMatch/Clinical Trials/NCT07499674

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

Is NCT07499674 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Abenacianine for lung cancer.

Phase 3RecruitingVergent Bioscience, Inc.NCT07499674Data as of Jun 2026Location: United States · Australia

Treatment: AbenacianineThis is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging in participants undergoing surgery for cancer in the lung. Approximately 132 partiipants will be enrolled to ensure a minimum of 115 evaluable participants receiving abenacianine and undergoing NIR imaging and a control group of 12 participants who will receive abenacianine but no NIR imaging.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Abenacianine

Cancer type

Non-Small Cell Lung Carcinoma

Small Cell Lung Cancer

Prior therapy

Cannot have received: chemotherapy

They have received chemotherapy...within 4 weeks prior to study enrollment.

Cannot have received: immunotherapy

They have received...immunotherapy...within 4 weeks prior to study enrollment.

Cannot have received: radiotherapy

They have received...radiotherapy within 4 weeks prior to study enrollment.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • City of Hope National Medical Center · Duarte, California
  • Orlando Health Cancer Center · Orlando, Florida
  • Mayo Clinic · Rochester, Minnesota
  • Hospital of the University of Pennsylvania · Philadelphia, Pennsylvania
  • University of Texas, MD Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT07499674 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior chemotherapy, immunotherapy, radiotherapy disqualifies patients from enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify